This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/business/live/2018/mar/28/markets-nervous-after-tech-shakeout-and-ahead-of-us-gdp-business-live
The article has changed 10 times. There is an RSS feed of changes available.
| Version 8 | Version 9 |
|---|---|
| Shire jumps on possible offer from Japan's Takeda, markets nervous after tech shakeout - as it happened | |
| (about 1 hour later) | |
| It was another volatile session for stock markets. | |
| After Tuesday’s slump on Wall Street, driven predominantly by sharp declines in technology stocks, European markets opened mostly lower. | |
| However they came off their worst levels as the US market managed to stage a mild recovery, with the Dow Jones Industrial Average currently marginally in positive territory, up 35 points, although the tech-heavy Nasdaq is down around 1%. Amazon in particular is being hit by reports that the US president plans to go after the company and altering its tax treatment. | |
| The FTSE 100, now up around 9 points, was supported by news of a potential bid for UK listed pharmaceutical group Shire from Japan’s Takeda. Shire’s shares jumped, valuing the company at more than £35bn at one point. | |
| Elsewhere there was more bad news for the UK high street, with retail sales falling in March for the first time since October, according to the CBI. | |
| But the US economy grew more strongly than expected in the final quarter. And there was a positive report on the eurozone economy from S&P Global ratings. | |
| On that note, it’s time to close for the day. Thanks for all your comments, and we’ll be back tomorrow. | |
| Back with Shire, and Ketan Patel at EdenTree Investment Management says it could be a key moment if a deal goes ahead: | |
| If a bid does materialise from Takeda for drug maker Shire, it would be a watershed moment for Japanese pharma. There hasn’t been a cross border transaction in the sector, excluding joint ventures and small generic M&A. Takeda’s cash laden balance sheet appears a good fit for Shire’s struggling balance sheet, following recent large scale M&A. | |
| The attraction for Takeda is the highly lucrative rare disease market in the US, which comes with exceedingly high margins and is largely exempt from the usual pricing pressure that affects the wider pharmaceutical sector. | |
| After Tuesday’s tech-inspired slump, there is little respite for the sector despite US markets generally starting the day on a slightly more positive note. | |
| The Dow Jones Industrial Average is up 121 points or 0.53% in early trading, while the S&P 500 has edged up 0.05%. But the tech-heavy Nasdaq Composite has opened down 0.35%. | |
| The stronger than expected US GDP figure will revive talk about how many interest rate rises the Federal Reserve will sanction this year. Dennis de Jong, managing director at UFX.com, said: | The stronger than expected US GDP figure will revive talk about how many interest rate rises the Federal Reserve will sanction this year. Dennis de Jong, managing director at UFX.com, said: |
| Robust jobs growth and healthy consumer spending have been attributed to today’s stronger than expected US GDP data, as the country’s economic outlook appears in rude health and the 3% growth target appears within touching distance. | Robust jobs growth and healthy consumer spending have been attributed to today’s stronger than expected US GDP data, as the country’s economic outlook appears in rude health and the 3% growth target appears within touching distance. |
| ...As a result of the strong economic outlook, questions may be raised around the possibility of Fed Chair Jerome Powell introducing a June rate hike. | ...As a result of the strong economic outlook, questions may be raised around the possibility of Fed Chair Jerome Powell introducing a June rate hike. |
| It may be a case of US growth being monitored before any rate decision is made, but markets could be volatile between now and then. | It may be a case of US growth being monitored before any rate decision is made, but markets could be volatile between now and then. |
| The 2.9% growth in the US economy, although better than the initial estimates, shows a slowdown from the 3.2% rise recorded in the third quarter. | The 2.9% growth in the US economy, although better than the initial estimates, shows a slowdown from the 3.2% rise recorded in the third quarter. |
| The figures were helped by the biggest rise in consumer spending for three years, offset by a surge in imports. The Bureau of Economic Analysis said: | The figures were helped by the biggest rise in consumer spending for three years, offset by a surge in imports. The Bureau of Economic Analysis said: |
| The increase in real GDP in the fourth quarter primarily reflected positive contributions from personal consumption expenditures, nonresidential fixed investment, exports, residential fixed investment, state and local government spending, and federal government spending that were partly offset by a negative contribution from private inventory investment. Imports, which are a subtraction in the calculation of GDP, increased. | The increase in real GDP in the fourth quarter primarily reflected positive contributions from personal consumption expenditures, nonresidential fixed investment, exports, residential fixed investment, state and local government spending, and federal government spending that were partly offset by a negative contribution from private inventory investment. Imports, which are a subtraction in the calculation of GDP, increased. |
| Breaking news: | Breaking news: |
| Something for Donald Trump to tweet about. The US economy grew more strongly than expected in the final quarter, up 2.9% on an annualised basis compared to expectations of a 2.7% increase and an initial estimate of 2.5% growth. | Something for Donald Trump to tweet about. The US economy grew more strongly than expected in the final quarter, up 2.9% on an annualised basis compared to expectations of a 2.7% increase and an initial estimate of 2.5% growth. |
| Here’s some analyst reaction to the possible Shire deal. Peter Welford at Jefferies says the structure of any deal is uncertain: | Here’s some analyst reaction to the possible Shire deal. Peter Welford at Jefferies says the structure of any deal is uncertain: |
| We see the potential strategic rationale for the deal and have long highlighted Shire is currently trading at a substantial discount to our fundamental 4300p or so value given overhangs, notably haemophilia competitive concerns. Nevertheless Takeda’s near.$42bn market cap versus Shire’s $47bn or $66bn enterprise value raises questions on a potential deal structure.... | We see the potential strategic rationale for the deal and have long highlighted Shire is currently trading at a substantial discount to our fundamental 4300p or so value given overhangs, notably haemophilia competitive concerns. Nevertheless Takeda’s near.$42bn market cap versus Shire’s $47bn or $66bn enterprise value raises questions on a potential deal structure.... |
| We presume Takeda would need a significant equity raise to acquire Shire, suggesting a “merger” is perhaps better terminology, which may raise hurdles to the successful completion of any future deal. | We presume Takeda would need a significant equity raise to acquire Shire, suggesting a “merger” is perhaps better terminology, which may raise hurdles to the successful completion of any future deal. |
| Jack Scannell at UBS says other bidders could emerge: | Jack Scannell at UBS says other bidders could emerge: |
| Since Takeda’s market cap is close to Shire’s we assume a potential offer would have to include a substantial percentage in equity and how Shire’s board and shareholders would react is hard to predict. However as Shire’s share price is significantly below the net present value of our cash flow estimates, Takeda could trigger discussion of other bidders. | Since Takeda’s market cap is close to Shire’s we assume a potential offer would have to include a substantial percentage in equity and how Shire’s board and shareholders would react is hard to predict. However as Shire’s share price is significantly below the net present value of our cash flow estimates, Takeda could trigger discussion of other bidders. |
| Shire does not strike us as an obvious take-over candidate. There is presumably a price at which the financial engineering would work. However, Shire’s specialty focus and mix of therapeutic foci means that most buyers would struggle to extract substantial operational synergies while escaping from competition problems, in our view. Also Shire’s low corporate tax rate could rise in most scenarios were the company acquired. It would also be a bold acquisition in our view given the uncertain trajectory of Shire’s haemophilia business. A merger of equals in this context might be more feasible. | Shire does not strike us as an obvious take-over candidate. There is presumably a price at which the financial engineering would work. However, Shire’s specialty focus and mix of therapeutic foci means that most buyers would struggle to extract substantial operational synergies while escaping from competition problems, in our view. Also Shire’s low corporate tax rate could rise in most scenarios were the company acquired. It would also be a bold acquisition in our view given the uncertain trajectory of Shire’s haemophilia business. A merger of equals in this context might be more feasible. |
| The potential offer for Shire has helped the FTSE 100 come off its worst levels after the morning’s earlier declines. | The potential offer for Shire has helped the FTSE 100 come off its worst levels after the morning’s earlier declines. |
| The UK’s leading index is now down just 0.12% or around 8 points, with Shire up 18% and fellow drugs group GlaxoSmithKline 1.5% better. | The UK’s leading index is now down just 0.12% or around 8 points, with Shire up 18% and fellow drugs group GlaxoSmithKline 1.5% better. |
| Elsewhere though the fallout from the US tech slump continues. Germany’s Dax remains down 0.7%, while France’s Cac is 0.9% lower. | Elsewhere though the fallout from the US tech slump continues. Germany’s Dax remains down 0.7%, while France’s Cac is 0.9% lower. |
| Meanwhile US futures are suggesting a rebound of sorts on Wall Street, with the Dow Jones Industrial Average forecast to open around 67 points higher. | Meanwhile US futures are suggesting a rebound of sorts on Wall Street, with the Dow Jones Industrial Average forecast to open around 67 points higher. |
| Here’s our story on the possible takeover of Shire by Japan’s Takeda: | Here’s our story on the possible takeover of Shire by Japan’s Takeda: |
| Shares in the UK-listed drugmaker Shire surged after Japan’s biggest pharmaceutical company, Takeda Pharmaceutical, said it was considering making a takeover approach. | Shares in the UK-listed drugmaker Shire surged after Japan’s biggest pharmaceutical company, Takeda Pharmaceutical, said it was considering making a takeover approach. |
| Shire’s shares jumped as much as 33% to £38.79 on the news, and later traded 17% higher at £36, valuing the company at £32.8bn. Takeda’s market value is about £29bn, around the same as Shire’s at last night’s closing price. | Shire’s shares jumped as much as 33% to £38.79 on the news, and later traded 17% higher at £36, valuing the company at £32.8bn. Takeda’s market value is about £29bn, around the same as Shire’s at last night’s closing price. |
| Shire is best known for its ADHD drug Adderall but its focus in recent years has been on rare diseases. The company is based in Dublin for tax purposes but run from Boston. Most of its operations are in the US. | Shire is best known for its ADHD drug Adderall but its focus in recent years has been on rare diseases. The company is based in Dublin for tax purposes but run from Boston. Most of its operations are in the US. |
| The news comes three-and-a-half years after US firm AbbVie abandoned its agreed $54bn (£34bn) takeover of Shire, after a US clampdown on so-called tax inversions by US companies buying an overseas business to secure a lower tax rate. | The news comes three-and-a-half years after US firm AbbVie abandoned its agreed $54bn (£34bn) takeover of Shire, after a US clampdown on so-called tax inversions by US companies buying an overseas business to secure a lower tax rate. |
| Shire then turned acquiror and completed its $32bn purchase of US firm Baxalta last June. In November it reported a drop in sales of haemophilia drugs, which became its biggest source of revenue following the deal. | Shire then turned acquiror and completed its $32bn purchase of US firm Baxalta last June. In November it reported a drop in sales of haemophilia drugs, which became its biggest source of revenue following the deal. |
| The full report is here: | The full report is here: |
| Here is the full statement from Takeda, which includes more detail of the Japanese company’s thinking: | Here is the full statement from Takeda, which includes more detail of the Japanese company’s thinking: |
| Takeda believes that a potential transaction with Shire presents an opportunity to advance Takeda’s stated Vision 2025, build on its current strong momentum, and create a truly global, value-based Japanese biopharmaceutical leader. In particular, a transaction with Shire would: | Takeda believes that a potential transaction with Shire presents an opportunity to advance Takeda’s stated Vision 2025, build on its current strong momentum, and create a truly global, value-based Japanese biopharmaceutical leader. In particular, a transaction with Shire would: |
| · strengthen Takeda’s core therapeutic areas of oncology, GI and neuroscience | · strengthen Takeda’s core therapeutic areas of oncology, GI and neuroscience |
| · accelerate Takeda’s vision to be a leader in specialized medicines that are transformative to patients through the addition of Shire’s leading global rare disease franchise | · accelerate Takeda’s vision to be a leader in specialized medicines that are transformative to patients through the addition of Shire’s leading global rare disease franchise |
| · further enhance Takeda’s robust R&D strategy, concentrating on key therapeutic areas | · further enhance Takeda’s robust R&D strategy, concentrating on key therapeutic areas |
| · reinforce a strong and large-molecule focused late-stage pipeline within Takeda’s core therapeutic areas to complement Takeda’s own pipeline and discovery capabilities | · reinforce a strong and large-molecule focused late-stage pipeline within Takeda’s core therapeutic areas to complement Takeda’s own pipeline and discovery capabilities |
| · balance Takeda’s geographic focus to align with the market opportunity in the U.S. | · balance Takeda’s geographic focus to align with the market opportunity in the U.S. |
| · drive financial value from a strong combined financial profile | · drive financial value from a strong combined financial profile |
| Clearly defined strategic and financial objectives are core to Takeda’s disciplined approach to acquisitions, including in relation to its dividend policy and credit rating, which are well-established. Any potential offer for Shire, if made, would have to align with this strict investment criteria. | Clearly defined strategic and financial objectives are core to Takeda’s disciplined approach to acquisitions, including in relation to its dividend policy and credit rating, which are well-established. Any potential offer for Shire, if made, would have to align with this strict investment criteria. |
| Back to Shire: | Back to Shire: |
| Shire's been tipped as a takeover target for ages - Takeda biting | Shire's been tipped as a takeover target for ages - Takeda biting |
| Shire #SHP shares adding 18pts to the FTSE 100 today and lifting it off the lows - announcement at 10:23 clear to sees on index pic.twitter.com/DzDRxo8yUb | Shire #SHP shares adding 18pts to the FTSE 100 today and lifting it off the lows - announcement at 10:23 clear to sees on index pic.twitter.com/DzDRxo8yUb |